Spurred by pricey Gilead hep C drug, payers cook up new cost-control moves
"Gilead Sciences' hepatitis C drug Sovaldi may mark a tipping point. Undoubtedly a breakthrough treatment, Sovaldi bears an undoubtedly high price tag: $84,000 for 12 weeks of treatment. And payers, seeing the number of high-priced therapies now on the market, with more in the pipeline, are balking.
As Bloomberg reports, the Sovaldi launch has pharmacy benefits managers casting about for new tactics to control drug spending--and those new tactics could sap the power from some long-standing pharma strategies.
PBMs might refuse to pay a higher price for drugs that are more convenient to take than cheaper alternatives are. They might not cover all new drugs in a new generation of treatments, opting to analyze the field and choose the best--and most cost-effective--option. They might even bring in outside experts to review the data, just as cost-effectiveness watchdogs in other countries do."Read more: Spurred by pricey Gilead hep C drug, payers cook up new cost-control moves - FiercePharma http://www.fiercepharma.com/story/spurred-pricey-gilead-hep-c-drug-payers-cook-new-cost-control-moves/2014-01-27#ixzz2rcor2tar
1300 Wilson Boulevard Suite 300 Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2014 Infectious Diseases Society of America